TheStreet
JIM CRAMERINVESTINGPERSONAL FINANCERETIREMENTCRYPTOMARKETSHOW-TOVIDEOFINANCIAL ADVISOR CENTERTECHNOLOGY
Search
PRESS RELEASES

Marker Therapeutics To Present At The Virtual Oppenheimer 31st Annual Healthcare Conference

PRESS RELEASES

Marker Therapeutics, Inc. Announces Pricing Of Public Offering Of Common Stock

PRESS RELEASES

Marker Therapeutics, Inc. Announces Proposed Public Offering Of Common Stock

PRESS RELEASES

Marker Therapeutics Announces Dosing Of First Patient In Phase 2 Trial Of MT-401 In Acute Myeloid Leukemia Following Stem Cell Transplant

PRESS RELEASES

Marker Therapeutics Announces Completion Of New Manufacturing Facility To Support Clinical Development Of MultiTAA-Specific T Cell Therapy Product Candidates

PRESS RELEASES

Marker Therapeutics Announces FDA Lifted Partial Clinical Hold On Phase 2 AML Clinical Trial

PRESS RELEASES

Marker Therapeutics To Host Third Quarter 2020 Operating And Financial Results Conference Call And Webcast On Monday, November 9, 2020

PRESS RELEASES

Marker Therapeutics To Present At The Virtual Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

PRESS RELEASES

Marker Therapeutics Announces New Manufacturing Facility To Support Clinical Development Of MultiTAA-Specific T Cell Therapy Product Candidates

PRESS RELEASES

Marker Therapeutics Receives USAN Approval For "zelenoleucel" As Nonproprietary Name For MT-401, Multi-Tumor-Associated Antigen Targeted T Cell Product For Acute Myeloid Leukemia

PRESS RELEASES

Marker Therapeutics To Host First Quarter 2020 Operating And Financial Results Conference Call And Webcast On Monday, May 11, 2020

PRESS RELEASES

Marker Therapeutics Receives FDA Orphan Drug Designation For Its Multi-Antigen Targeted T Cell Therapy For Acute Myeloid Leukemia

PRESS RELEASES

Marker Therapeutics And Aspire Capital Enter Into A Common Stock Purchase Agreement For Up To $30 Million

PRESS RELEASES

Marker Therapeutics To Present At Two Upcoming Investor Conferences

PRESS RELEASES

Marker Therapeutics Announces Update To Its Clinical Program In AML